New & Noteworthy

Submit New & Noteworthy

November 2018

Butalbital Acetaminophen Capsule

Mayne Pharma (USA) Inc

Butalbital Acetaminophen Capsule

Mayne Pharma Group announces the launch of the butalbital acetaminophen (APAP) capsule 50 mg/300 mg in the United States. This is a new capsule formulation of butalbital/APAP, which is indicated for the treatment of tension headache (migraine). Complementary to Mayne Pharma’s butalbital/APAP tablet 50 mg/300 mg, this capsule formulation provides alternative treatment choices for patients who previously only had a tablet option. The company expects several product launches within the coming year, with 14 drug applications pending US FDA approval.

Mayne Pharma (USA) Inc

Click here to view product detail on Findit.

Recent Popular Articles

October 2019 : Cleanrooms & Compounding
October 2019 : Cleanrooms & Compounding
October 2019 : Cleanrooms & Compounding
November 2019

Current Issue

Enter our Sweepstakes now for your chance to win the following prizes:

Just answer the following quick question for your chance to win:

To continue, you must either login or register: